JP2018533618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533618A5 JP2018533618A5 JP2018529732A JP2018529732A JP2018533618A5 JP 2018533618 A5 JP2018533618 A5 JP 2018533618A5 JP 2018529732 A JP2018529732 A JP 2018529732A JP 2018529732 A JP2018529732 A JP 2018529732A JP 2018533618 A5 JP2018533618 A5 JP 2018533618A5
- Authority
- JP
- Japan
- Prior art keywords
- size
- less
- range
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 4
- 201000009623 Myopathy Diseases 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 239000002994 raw material Substances 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000004220 muscle function Effects 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 206010049565 Muscle fatigue Diseases 0.000 claims 1
- 235000019482 Palm oil Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003240 coconut oil Substances 0.000 claims 1
- 235000019864 coconut oil Nutrition 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000005313 fatty acid group Chemical group 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 239000002540 palm oil Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- -1 softgel Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 229930186301 urolithin Natural products 0.000 claims 1
- 0 *c(c(*)c1N)c(-c(c(C(O2)=O)c3C=C)c(*)c(N)c3O)c2c1N Chemical compound *c(c(*)c1N)c(-c(c(C(O2)=O)c3C=C)c(*)c(N)c3O)c2c1N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022144671A JP2022177130A (ja) | 2015-08-28 | 2022-09-12 | ウロリチン化合物を含む組成物 |
| JP2024174863A JP2025004129A (ja) | 2015-08-28 | 2024-10-04 | ウロリチン化合物を含む組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1515387.7 | 2015-08-28 | ||
| GBGB1515387.7A GB201515387D0 (en) | 2015-08-28 | 2015-08-28 | Compositions |
| PCT/EP2016/070255 WO2017036992A1 (en) | 2015-08-28 | 2016-08-26 | Compositions comprising urolithin compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022144671A Division JP2022177130A (ja) | 2015-08-28 | 2022-09-12 | ウロリチン化合物を含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533618A JP2018533618A (ja) | 2018-11-15 |
| JP2018533618A5 true JP2018533618A5 (enExample) | 2019-10-03 |
| JP7227003B2 JP7227003B2 (ja) | 2023-02-21 |
Family
ID=54326542
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529732A Active JP7227003B2 (ja) | 2015-08-28 | 2016-08-26 | ウロリチン化合物を含む組成物 |
| JP2022144671A Pending JP2022177130A (ja) | 2015-08-28 | 2022-09-12 | ウロリチン化合物を含む組成物 |
| JP2024174863A Pending JP2025004129A (ja) | 2015-08-28 | 2024-10-04 | ウロリチン化合物を含む組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022144671A Pending JP2022177130A (ja) | 2015-08-28 | 2022-09-12 | ウロリチン化合物を含む組成物 |
| JP2024174863A Pending JP2025004129A (ja) | 2015-08-28 | 2024-10-04 | ウロリチン化合物を含む組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10695320B2 (enExample) |
| EP (1) | EP3340977B1 (enExample) |
| JP (3) | JP7227003B2 (enExample) |
| KR (2) | KR102822365B1 (enExample) |
| CN (1) | CN108289879A (enExample) |
| AU (1) | AU2016314987B2 (enExample) |
| BR (1) | BR112018003745B1 (enExample) |
| CA (1) | CA2996724C (enExample) |
| ES (1) | ES2936723T3 (enExample) |
| GB (1) | GB201515387D0 (enExample) |
| MX (1) | MX2018002543A (enExample) |
| PT (1) | PT3340977T (enExample) |
| RU (1) | RU2754761C2 (enExample) |
| SG (1) | SG10202001793PA (enExample) |
| WO (1) | WO2017036992A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| WO2018162650A1 (en) * | 2017-03-08 | 2018-09-13 | Amazentis Sa | Methods for improving mitophagy in subjects |
| US20210267932A1 (en) | 2018-05-15 | 2021-09-02 | University Of Louisville Research Foundation, Inc. | Compounds, compositions, methods of using, and methods for preparing compounds |
| GB201916046D0 (en) * | 2019-11-04 | 2019-12-18 | Amazentis Sa | Diagnostic method |
| CA3188397A1 (en) | 2020-09-25 | 2022-03-31 | Anupama Dattatreya | Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix |
| JP7541673B2 (ja) * | 2020-11-30 | 2024-08-29 | 国立研究開発法人産業技術総合研究所 | 筋ジストロフィーの抗炎症剤、筋ジストロフィーにおける抗炎症のための中心静脈栄養用組成物および筋ジストロフィーの抗炎症用食品組成物 |
| KR102623664B1 (ko) | 2020-12-10 | 2024-01-12 | 서울대학교산학협력단 | 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법 |
| CN117015530A (zh) | 2021-01-27 | 2023-11-07 | 范徳利亚股份公司 | 尿石素衍生物及其使用方法 |
| EP4085906A1 (en) * | 2021-05-06 | 2022-11-09 | Universite De Bordeaux | Composition comprising ppar-modulator and an urolithin derivative and uses thereof |
| CN113813255B (zh) * | 2021-10-20 | 2023-09-01 | 山东大学 | 尿石素a及其衍生物在肿瘤免疫治疗的应用 |
| WO2023199908A1 (ja) * | 2022-04-11 | 2023-10-19 | 株式会社ダイセル | 乳化組成物の製造方法 |
| GB202219317D0 (en) * | 2022-12-20 | 2023-02-01 | Amazentis Sa | Methods for improving mitophagy in subjects |
| EP4642448A1 (en) * | 2022-12-27 | 2025-11-05 | Indian Institute of Science | A method for the treatment of epilepsy |
| GB202316295D0 (en) | 2023-10-24 | 2023-12-06 | Amazentis Sa | Composition |
| EP4555997A1 (en) * | 2023-11-15 | 2025-05-21 | Science4Beauty Sp. z o.o. | Water-soluble composition comprising urolithin |
| GB202319994D0 (en) | 2023-12-22 | 2024-02-07 | Amazentis Sa | Compositions for use |
| KR20250158913A (ko) | 2024-04-30 | 2025-11-07 | 주식회사 파이안바이오테크놀로지 | 유로리틴을 함유하는 탈모완화제와 모발성장촉진제 |
| WO2025252771A1 (en) | 2024-06-03 | 2025-12-11 | Amazentis Sa | Urolithin combinations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3786447B2 (ja) * | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Ｃ型肝炎の予防・治療剤 |
| AU723797B2 (en) | 1996-03-26 | 2000-09-07 | Eli Lilly And Company | Benzothiophenes, formulations containing same, and methods |
| WO1999053941A1 (fr) * | 1998-04-15 | 1999-10-28 | Shionogi & Co., Ltd. | Preparations orales contenant des derives de trh |
| AU2681300A (en) | 1999-02-22 | 2000-09-14 | Elan Corporation, Plc | Solid oral dosage form containing an enhancer |
| US6623734B2 (en) * | 2000-06-22 | 2003-09-23 | Soft Gel Technologies, Inc. | Super absorption coenzyme Q10 |
| US20050282781A1 (en) | 2004-06-18 | 2005-12-22 | Shibnath Ghosal | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids |
| JP5147239B2 (ja) | 2004-09-29 | 2013-02-20 | 三栄源エフ・エフ・アイ株式会社 | コエンザイムｑ１０含有乳化組成物 |
| US20060257337A1 (en) * | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| US8894993B2 (en) * | 2006-08-04 | 2014-11-25 | Natreon Inc. | Mitochondria-targeted antioxidants |
| EP2145904A1 (de) | 2008-07-18 | 2010-01-20 | Basf Se | Verfahren zur enzymkatalysierten Hydrolyse von Polyacrylsäureestern sowie dafür zu verwendende Esterasen |
| CA2737456C (en) | 2008-09-17 | 2017-05-23 | Chiasma Inc. | Pharmaceutical compositions and related methods of delivery |
| US20110182985A1 (en) | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| RU2657750C1 (ru) | 2010-03-19 | 2018-06-15 | Бостон Байомедикал, Инк. | Новые способы направленного воздействия на раковые стволовые клетки |
| AU2011232103B2 (en) | 2010-03-22 | 2013-10-24 | Instillo Gmbh | Method and device for producing microparticles or nanoparticles |
| CA2796494A1 (en) | 2010-04-20 | 2011-10-27 | Cipla Limited | Pharmaceutical composition |
| JP2013544829A (ja) | 2010-11-24 | 2013-12-19 | エクセリクシス， インク． | ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピンおよびその使用と製造方法 |
| JP2012111712A (ja) | 2010-11-25 | 2012-06-14 | Toyo Capsule Kk | 油性ビタミンｃ経口投与用組成物 |
| EP4578500A3 (en) * | 2010-12-23 | 2025-09-17 | Amazentis SA | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders |
| JP2014501784A (ja) | 2011-01-07 | 2014-01-23 | メリオン・リサーチ・Ｉｉｉ・リミテッド | 経口投与用の鉄の医薬組成物 |
| CA2826884A1 (en) * | 2012-09-14 | 2014-03-14 | Natreon, Inc. | Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit |
| GB201323008D0 (en) * | 2013-12-24 | 2014-02-12 | Amazentis As | Compounds and uses thereof |
| GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| GB201515387D0 (en) | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
-
2015
- 2015-08-28 GB GBGB1515387.7A patent/GB201515387D0/en not_active Ceased
-
2016
- 2016-08-26 US US15/757,293 patent/US10695320B2/en active Active
- 2016-08-26 EP EP16757263.5A patent/EP3340977B1/en active Active
- 2016-08-26 MX MX2018002543A patent/MX2018002543A/es unknown
- 2016-08-26 SG SG10202001793PA patent/SG10202001793PA/en unknown
- 2016-08-26 PT PT167572635T patent/PT3340977T/pt unknown
- 2016-08-26 KR KR1020247012842A patent/KR102822365B1/ko active Active
- 2016-08-26 CA CA2996724A patent/CA2996724C/en active Active
- 2016-08-26 BR BR112018003745-1A patent/BR112018003745B1/pt active IP Right Grant
- 2016-08-26 ES ES16757263T patent/ES2936723T3/es active Active
- 2016-08-26 RU RU2018108136A patent/RU2754761C2/ru active
- 2016-08-26 KR KR1020187007291A patent/KR102660005B1/ko active Active
- 2016-08-26 WO PCT/EP2016/070255 patent/WO2017036992A1/en not_active Ceased
- 2016-08-26 JP JP2018529732A patent/JP7227003B2/ja active Active
- 2016-08-26 AU AU2016314987A patent/AU2016314987B2/en active Active
- 2016-08-26 CN CN201680050456.6A patent/CN108289879A/zh active Pending
-
2020
- 2020-06-15 US US16/901,182 patent/US11337957B2/en active Active
-
2022
- 2022-05-05 US US17/737,605 patent/US11925616B2/en active Active
- 2022-09-12 JP JP2022144671A patent/JP2022177130A/ja active Pending
-
2024
- 2024-01-19 US US18/417,794 patent/US20240148690A1/en not_active Abandoned
- 2024-10-04 JP JP2024174863A patent/JP2025004129A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533618A5 (enExample) | ||
| RU2018108136A (ru) | Композиции, содержащие уролитины | |
| ES2585066T3 (es) | Composiciones para el tratamiento de trastornos neurológicos | |
| BR112013019732B1 (pt) | Composição farmacêutica e seu uso no tratamento de doenças cardiovasculares | |
| JP2015531344A5 (enExample) | ||
| RU2017139767A (ru) | Концентрированные терапевтические фосфолипидные композиции | |
| BR112017017310B1 (pt) | Composições lipídicas e suplemento alimentar ou nutricional, alimento médico ou funcional e veículo de liberação oral compreendendo as ditas composições | |
| CN104187627A (zh) | 一种降血脂组合物及其在制备具有降血脂功能的保健食品中的应用 | |
| RU2020118504A (ru) | Двойные эмульсии | |
| JP2014530204A5 (enExample) | ||
| JP6519087B2 (ja) | カロチノイド化合物の異性体比の維持のための新規方法 | |
| TWI669062B (zh) | Composition containing high amounts of sesamin | |
| JP7157743B2 (ja) | ケトン体生成促進剤 | |
| WO2015185238A1 (en) | Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration | |
| KR102671055B1 (ko) | 분리대두단백 및 커큐민을 포함하는 운동수행능력 향상용 조성물 | |
| JP6519875B2 (ja) | 改良された魚油ベースのオメガ３補助食品 | |
| JP6824506B2 (ja) | 脂質組成物 | |
| CN106456587B (zh) | 含有欧米茄-3和白藜芦醇的固体制剂 | |
| HK1257500B (en) | Compositions comprising urolithin compounds | |
| WO2015163091A1 (ja) | 不飽和脂肪酸の吸収促進剤 |